Agios Pharmaceuticals (AGIO) Return on Capital Employed (2013 - 2026)
Agios Pharmaceuticals (AGIO) posted Return on Capital Employed of 40.22% for Q1 2026, down 7.28% on a QoQ basis from 37.49% in Q4 2025, and down 1194.0% year-over-year from 3.68% in Q1 2025.
Agios Pharmaceuticals (AGIO) Return on Capital Employed (2013 - 2026) Analysis & Trends
Agios Pharmaceuticals' Return on Capital Employed history runs 14 years deep, the most recent figure standing at 40.22% for Q1 2026.
- Quarterly Return on Capital Employed fell 1194.0% year-over-year to 40.22% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 40.22% (down 1194.0% YoY) and the FY2025 annual result came in at 33.77%, up 115.0% from the prior year.
- Return on Capital Employed was 40.22% for Q1 2026 at Agios Pharmaceuticals, down from 37.49% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 25.86% in Q4 2024 and bottomed at 54.1% in Q2 2024.
- A 5-year average of 36.1% and a median of 34.99% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed plunged 1886 bps — and 2025, when it jumped 2211 bps.
- Agios Pharmaceuticals' Return on Capital Employed stood at 33.92% in 2022, then retreated by 28 bps to 43.29% in 2023, then soared by 40 bps to 25.86% in 2024, then tumbled by 45 bps to 37.49% in 2025, then slipped by 7 bps to 40.22% in 2026.
- Business Quant data shows AGIO's Return on Capital Employed at 40.22% in Q1 2026, 37.49% in Q4 2025, and 35.13% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Agios Pharmaceuticals | 2.13 Bn | 2.13 Bn | 19.43 Mn | -40.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -40.22% |
| Dec 31, 2025 | -37.49% |
| Sep 30, 2025 | -35.13% |
| Jun 30, 2025 | -31.98% |
| Mar 31, 2025 | -28.28% |
| Dec 31, 2024 | -25.86% |
| Sep 30, 2024 | -34.99% |
| Jun 30, 2024 | -54.10% |
| Mar 31, 2024 | -46.68% |
| Dec 31, 2023 | -43.29% |
| Sep 30, 2023 | -38.91% |
| Jun 30, 2023 | -35.23% |
| Mar 31, 2023 | -32.92% |
| Dec 31, 2022 | -33.92% |
| Sep 30, 2022 | -33.94% |
| Jun 30, 2022 | -31.69% |
| Mar 31, 2022 | -28.96% |
| Dec 31, 2021 | -26.47% |
| Sep 30, 2021 | -22.18% |
| Jun 30, 2021 | -16.75% |